Moleculin Biotech shares fall 27.51% premarket after warrant exercise raises $8.3M with dilutive new warrants.

Moleculin Biotech (MBRX) fell 27.51% in premarket trading following the announcement that warrant holders exercised 2.1 million shares at $3.90, raising $8.3 million, while the company agreed to issue new unregistered warrants exercisable for up to 6.3 million shares at potentially lower prices. The transaction, expected to close on February 20, 2026, introduces significant share dilution risk, as the new warrants—subject to shareholder approval—could further depress the stock price if exercised at a discount to current levels. While the firm cited proceeds for working capital, the market appears to have penalized the equity-linked financing structure, which may signal weakened investor confidence in the company’s valuation or growth prospects. Other recent updates, including progress in its MIRACLE trial for Annamycin, were likely overshadowed by the dilutive financing terms driving the sharp premarket decline.